“The Vall d’Hebron Institute of Oncology (VHIO) has enrolled the first patient in the NoCanTher project’s clinical trial, representing an important step in bringing in nano-driven therapeutics as novel weaponry in the current arsenal of anti-cancer technologies. Specifically, this multi-center Consortium, which launched in 2016 and is powered by eleven European partners, is leading the development of magnetic nanoparticles for the treatment of locally advanced pancreatic cancer.
When exposed to a time-varying magnetic field, these nanoparticles generate hyperthermia and directly destroy tumor cells. This novel strategy, in combination with chemotherapy, aims at inactivating cancer cells and achieving tumor shrinkage. In addition, the intracellular delivery of these nanoparticles promises to reduce the adverse effects associated with chemotherapy. VHIO is the very first Spanish research center to apply this nanotechnology-based therapy at the clinical level.”
For more information